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Introduction
Surgical excision is generally considered the preferred
treatment for unilateral acoustic neuromas in healthy,
non-elderly patients who have useful hearing in the
contralateral ear.1 The location and relationship of
such neuromas to neurovascular structures, and
adherence to the brain stem or cranial base, pose
challenges for preserving cranial nerve function, and
render complete surgical resection difficult in some
cases. Resection is frequently associated with the
development of new neurologic deficits.1–3
The clinical application of stereotactic radiosurgery
began in Sweden in 1967,4 and the first patient with
acoustic neuroma was treated in 1969.5 Since then,
major improvements in the accuracy and efficiency of
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stereotactic radiosurgery have resulted from
combination of the procedure with advanced high-
resolution imaging techniques such as magnetic
resonance imaging (MRI).6,7 In this report, we analyze
the preliminary results from 45 patients who underwent
radiosurgery as management for newly diagnosed or
recurrent acoustic schwannoma.
Methods
Patient population
During a 4-year period, 45 patients with unilateral
acoustic schwannomas underwent stereotactic
radiosurgery with a 201-source, cobalt-60 gamma
knife. Thirteen patients had undergone 1–3 (mean,
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l.4) previous surgical resections. Thirty-two patients
underwent radiosurgery on the basis of clinical findings
and imaging criteria. Tumors in these patients were
found along the course of the acoustic nerve, and had
the characteristics of vestibular schwannowa or acoustic
neuroma (cerebello-pontine angle location, and tail
extending into the internal acoustic meatus). In these
patients, radiosurgery was performed for 1 of the
following reasons: 1) the patient had little neurologic
deficit; 2) the patient was elderly or declined to
undergo microsurgical resection; or 3) the patient had
residual or recurrent tumors after surgical excision. Pa-
tient age ranged from 24 to 82 years (mean, 55 years).
Preoperative assessment
All patients had a detailed history taken, underwent a
physical examination, and preoperative high-resolution
MRI. All patients were evaluated with pure-tone
audiograms. Preoperative and postoperative hearing
was classified according to the system of Gardner and
Robertson,8 a modification of the Silverstein and
Norrell classification system, as shown in Table 1.
Radiosurgical technique
In all 45 patients, a Leksell Model G stereotactic
coordinate frame (Elekta Instruments, Atlanta, GA,
USA) was applied to the head, under local anesthesia
supplemented with mild oral or intravenous sedation.
A high-resolution, contrast-enhanced MRI scan was
performed to localize the target tumor. Multiple
isocenter computer dose planning was completed
using the GammaPlan® dose-planning system (Elekta
Instruments). Median tumor volume was 4.5 mL
(range, 0.5–30.0 mL), and mean maximum tumor
dose was 23 Gy (range, 22–28 Gy). Median tumor-
margin dose was 11.5 Gy (range, 10.5–14.0 Gy)
(Figure 1).
The margin dose was the dose selected to cover the
contrast-enhanced tumor margin, using the conformal
dose-planning technique. This dose served to cover
100% of the target volume. Using MRI, we found that
irregularities in tumor shape could be readily identified,
and greater numbers of isocenters were used to obtain
conformal irradiation. In 41 patients, the 50% isodose
line was targeted to the tumor margin, and in 4
patients, the 55% isodose line was targeted to the
tumor margin. The mean number of isocenters per
patient was 14 (range, 3–29). The dose selected was
based on tumor volume, although as low a dose as
possible was selected. Tumor location and the projected
radiobiologic risk to the adjacent brain stem and
cranial nerves were considered during dose planning.
Immediately after radiosurgery, all patients were given
a single intravenous dose of methylprednisolone 40
mg. All patients were discharged within 24 hours.
Postoperative evaluation
Follow-up ranged from 6 to 48 months (median, 25
months). Our protocol for post-radiosurgical
assessment included serial clinical examinations and
MRI scans at 3, 6 and 12 months during the first year,
and every 6 months thereafter. In patients with grade
IV or better hearing preoperatively, a pure-tone
audiogram was requested at the same intervals.
Table 1. Hearing classification in 45 patients with acoustic neuromas
Class description Pure tone average (dB) Speech discrimination score (%)
Number of tumors
Preoperative Postoperative
I 0–30 70–100 4 3
II 31–50 50–69 9 8
III 51–90 5–49 10 12
IV 91–maximum 1–4 8 8
V None detectable 0 14 14
Figure 1. Scatter plot of tumor volume versus tumor-margin dose
for radiosurgery in 45 patients with acoustic neuromas.
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Whenever possible, follow-up electrophysiologic
s tudies ,  inc luding evoked potent ia l ,  and
electromuscular electromyography, were performed,
especially if delayed facial or trigeminal nerve
dysfunction was reported.
Results
Eighty-five percent of patients were discharged from
the hospital within 24 hours after radiosurgery,
and all others within 48 hours. Fifteen percent of
patients experienced transient headaches, and 27%
had nausea and/or vomiting during the first 12
postoperative hours. These symptoms resolved after
treatment with mild analgesics and antiemetics. In
most cases, the single postoperative intravenous dose
of methylprednisolone 40 mg prevented these
symptoms.
Imaging responses
During the median follow-up period of 25 months
(range, 6–48 months), imaging studies showed a
reduction in tumor volume in 15 patients (33.3%) and
tumor-growth arrest in 28 patients (62.2%) (Table 2).
Imaging revealed evidence of central tumor necrosis in
29 patients (64.4%). Thirteen of these patients
eventually showed regression in tumor volume; the
volume of central necrosis paralleled the reduction in
tumor size (Figure 2). None of the patients developed
local brain stem, high T2-signal MRI changes on
long-repetition time images.
Clinical responses
The preoperative and postoperative hearing
classification of 45 patients is presented in Table 1.
Audiologic follow-up was performed 6–48 months
(median, 18 months) after radiosurgery. Thirteen
patients had either good (grade I) or serviceable
(grade II) hearing preoperatively. Ten patients retained
good or serviceable hearing postoperatively, but 3
developed hearing impairment. Improvement of
preoperative hearing impairment was observed in 1
patient postoperatively. Preoperative examination had
disclosed facial weakness in 15 patients, trigeminal
sensory loss in 7, and reports of imbalance or ataxia in
6. These signs were usually relatively mild. In the
follow-up period, no delayed facial nerve dysfunction
occurred, and there was no exacerbation of preoperative
complaints. Delayed trigeminal nerve dysfunction was
observed in 1 patient. Another patient underwent
microscopic removal of the tumor because of worsening
ataxia 9 months after radiosurgery, although the tumor
volume had not increased. One patient died from
unrelated disease after 1.5 years of follow-up.
Discussion
Tumor control after radiosurgery
Although total tumor removal remains a reasonable
goal of vestibular schwannoma surgery, alternative
strategies must play a role in management because
recurrence after subtotal resection is not rare. Therapeutic
options for recurrent or residual tumors after surgery
include re-operation, fractionated external-beam
radiotherapy, and stereotactic radiosurgery.
Table 2. Postoperative magnetic resonance imaging results in 45 patients with acoustic neuromas
Change in tumor volume Overall, n (%) Loss of central enhancement, n (%)
Increased 2 (4.4) 0 (0)
Unchanged 28 (62.2) 16 (55.2)
Decreased 15 (33.3) 13 (44.8)
Figure 2. Axial plane, contrast-enhanced magnetic resonance
images obtained in a 25-year-old man who underwent gamma knife
radiosurgery (12 Gy at margin; 50% isocenter): (A) left-sided
acoustic neuroma; (B) swollen tumor was seen 6 months after
treatment; (C) tumor regression was noted 12 months later.
(D, F) Preoperative hearing level was maintained after treatment,
although (E) transient impairment was noted at the sixth month.
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The goal of radiosurgery is to achieve tumor
control with a low risk of additional cranial nerve
deficits. Further, the efficacy of radiosurgery in the
treatment of vestibular schwannoma is reflected by
the increasing number of patients managed at our
center and others.9,10 The radiobiologic mechanism
of growth control achieved via radiosurgery is believed
to be a combination of direct tumoricidal effects and
delayed intratumoral vascular obliteration. In vitro
studies suggest that Schwann cells are irreversibly
damaged after a single-fraction radiation dose as low
as 30 Gy.11 It is thought that the tumor-cell response
is both time-dependent and dose-dependent.
Our imaging studies showed that 1-third of patients
had reduced tumor volume, and 62.2% had unchanged
tumor size. However, Kondziolka et al9 followed
patients for a much longer time (5–10 years) after
treatment at Pittsburgh University. These investigators
noted a total tumor control rate of 98%, and reductions
in tumor size of 25.5% in year 1, 46.9% in year 2, 58.8%
in year 3, and 76.0% in year 5. Other reports revealed a
tumor control rate ranging from 89% to 100%.12,13
To confirm the efficacy of radiosurgery, we
compared the tumor control achieved by radiosurgery
in our study with the natural history of untreated
acoustic neuromas (Table 3). We reviewed all the
published reports and included the 3 largest groups
that provided definitive data about tumor growth (> 2
mm per year), no growth, and tumor regression.14–16
Tumor size in the control group increased in 107
patients, was unchanged in 118, and decreased in 17,
over an average follow-up period of 2.3 years. Based
on our radiosurgical results for acoustic tumors, and
on data from other investigators,14–16 radiosurgery
provides improved tumor control relative to untreated
individuals (p < 0.001, Chi-squared test).
Our early experience with acoustic neuromas has
shown that tumors with central necrosis after
radiosurgery often have delayed volume reduction.
Loss of central contrast enhancement may result from
radiation-induced vascular injury and occlusion.
Indeed, obliteration of blood supply to the tumor may
be 1 of the most significant mechanisms controlling
tumor growth after surgery. Although Noren et al17
reported that the absence of a post-radiosurgical
decrease in tumor size was unrelated to a loss of con-
trast enhancement, we found the latter factor to be a
good prognostic indicator of delayed tumor shrinkage.
Hearing preservation
Hearing preservation is a pertinent surgical goal in
relatively few patients with acoustic neuromas. The
initial rate of hearing preservation after surgery for
acoustic neuroma was 33%, as reported by Gardner
and Robertson.8 Samii and Matthies18 also reported a
39% rate of hearing preservation, and other groups
documented a tumor control rate of 15–48%.19,20
Seventy-eight percent of our patients remained at
the preoperative hearing level at follow-up, but further
follow-up is needed to verify this finding. In patients
with less than 90 dB pure tone average preoperative
hearing loss, Noren et al17 reported preserved hearing
in 56% of patients 1 year after radiosurgery, 54% at
2 years, and 28% at 6 years. Hirsh and Noren21 reported
9 patients with preoperative pure tone average values
of 55 dB or less who were treated with radiosurgery
and followed for 4–9 years. Two patients completely
lost their hearing, 3 had their hearing preserved, and
the remaining 4 experienced varying degrees of hearing
loss.21 Linskey et al22 reported 7 patients with serviceable
hearing preoperatively: 3 became deaf within the first
year of treatment; but in 4, hearing stayed within 1
level above or below their initial grade. Kondziolka et
al9 reported hearing preservation in 51% of patients
with a median dose of 15.5 Gy, and recently, hearing
preservation after radiosurgery for acoustic neuroma
Table 3. Comparison of tumor control achieved by radiosurgery with the untreated natural history of acoustic neuroma
(control group)
Natural history (n = 242) Stereotactic radiosurgery (n = 43)
Mean age, yr (range) 59 (11–81) 60 (24–74)
Mean duration of follow-up, yr (range) 2.3 (1.0–12.1) 2.5 (1.0–4.0)
Tumor condition, n (%)*
Disease progression 107 (44.2) 2 (4.7)
Partial response 118 (48.8) 23 (53.5)
Stable disease 17 (7.0) 18 (41.9)
*Outcomes between the 2 groups were significantly different (p < 0.001, Chi-squared test).
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appeared promising when patients were treated with a
dose lower than 15 Gy.23 Flickinger et al23 reported a
71% rate of hearing preservation when patients were
treated with a median dose of 13 Gy, and Petit et al24
reported that 87% of patients had hearing preserved
during audiogramic follow-up. A trend in our series,
and other reports, was that low-dose treatment had a
good hearing preservation effect without sacrificing
tumor control. Delayed hearing loss after radiosurgery
may be related to a direct radiation effect on the
cochlear division if it lies within the tumor, or to injury
of vascular supply to the cochlear nerve, or potentially,
to the cochlea itself, if it is inadvertently included in the
treated volume.
Other cranial nerve preservation
In our study, 1 patient showed trigeminal dysfunction
with sensory loss on 1 side of the face; other patients
had no further worsening of other cranial nerve
function. Further, in our patients, temporary or per-
manent postoperative facial paresis and trigeminal
neuropathy were less common than in the studies
conducted by Noren et al17 and Linskey et al.22 This
is not surprising because we selected 11–12 Gy as the
usual marginal tumor dose; in most patients, the
minimum effective dose is now generally accepted.
Based on the observations of Noren et al,17 most
patients with delayed trigeminal neuropathy will
recover. However, the mechanism of delayed cranial
nerve dysfunction remains unclear. Dysfunction
occurring several weeks to 6 months after radiation is
temporary, and appears to be related to demyelination.
Dysfunction occurring several months to years after
treatment may be associated with compromised
vascular supply.
Patients undergoing surgery for acoustic neuromas
consider adjustment to postoperative facial palsy to be
the most difficult problem. About 80% of patients have
temporary or permanent facial nerve dysfunction after
open surgery, although the facial nerve has been
preserved anatomically in 82–99% of patients in some
series.25–27 Facial nerve dysfunction in the immediate
postoperative period has been noted in 8–44% of
patients, and long-term follow-up studies found
restoration of normal facial nerve function in 46–100%
of patients.25–27
Low morbidity and a high rate of tumor control
were achieved in our series. There was no mortality or
major preoperative morbidity; hospitalization time
and costs were reduced compared with microsurgery;
and rates of hearing preservation, and trigeminal and
facial neuropathy were also more favorable than in
most of the best published reports of microsurgery.25–27
In conclusion, gamma knife radiosurgery is an
important alternative treatment for selected patients
with acoustic neuromas, especially in the elderly and in
patients with small- to moderate-sized tumors.
However, because of the low-dose treatment used in
most of our patients, a longer follow-up period is
needed to substantiate our findings.
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